Journal article
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
Abstract
Patients in complete cytogenetic response (CCyR) with detectable BCR-ABL1 after ≥2 years on imatinib were randomized to nilotinib (400 mg twice daily, n = 104) or continued imatinib (n = 103) in the Evaluating Nilotinib Efficacy and Safety in clinical Trials-Complete Molecular Response (ENESTcmr) trial. By 1 and 2 years, confirmed undetectable BCR-ABL1 was achieved by 12.5% vs 5.8% (P = .108) and 22.1% vs 8.7% of patients in the nilotinib and …
Authors
Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NCD; Dorlhiac Llacer PE; Schwarer AP; Mahon F-X; Rea D
Journal
Blood, Vol. 124, No. 5, pp. 729–736
Publisher
American Society of Hematology
Publication Date
July 31, 2014
DOI
10.1182/blood-2013-12-544015
ISSN
0006-4971